Northwest Bio halts enrollment for glioblastoma vax PhIII trial; Germany grants €30 million to East African Community for vaccines, health supply chain management;

> Enrollment for Northwest Bio's ($NWBO) Phase III trial of DCVax for glioblastoma has temporarily halted so its investigators can submit new information for regulatory review. Release

> Germany granted €70 million ($79 million) to the East African Community, €30 million ($34 million) of which will fund vaccines and health supply chain management. More

> There hasn't been a poison ivy vaccine since the 1980s, which was discontinued because it didn't meet new FDA efficacy standards. But an allergist in Pennsylvania is working on a new vaccine, made with poison ivy extract and ethanol. Story

> Pakistan launched a new polio vaccine to accelerate its campaign to eradicate the disease by 2016. Report

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.